End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.074 AUD | -2.63% | -3.90% | +25.42% |
Feb. 28 | Percheron Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
2023 | Dimerix Appoints Nonexecutive Chair | MT |
Sales 2024 * | 3.56M 2.31M | Sales 2025 * | 5.25M 3.41M | Capitalization | 66.71M 43.37M |
---|---|---|---|---|---|
Net income 2024 * | -17M -11.05M | Net income 2025 * | -31M -20.15M | EV / Sales 2024 * | 17 x |
Net cash position 2024 * | 6.1M 3.97M | Net cash position 2025 * | 17.41M 11.32M | EV / Sales 2025 * | 9.39 x |
P/E ratio 2024 * |
-3.89
x | P/E ratio 2025 * |
-1.76
x | Employees | 8 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.66% |
1 day | -2.63% | ||
1 week | -3.90% | ||
Current month | -10.84% | ||
1 month | -15.91% | ||
3 months | +25.42% | ||
6 months | +27.59% | ||
Current year | +25.42% |
Managers | Title | Age | Since |
---|---|---|---|
James Garner
CEO | Chief Executive Officer | - | 23-05-07 |
Phillip Hains
DFI | Director of Finance/CFO | 64 | 06-11-08 |
Anthony Filippis
COO | Chief Operating Officer | - | 22-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Phillip Hains
DFI | Director of Finance/CFO | 64 | 06-11-08 |
Ben Price
BRD | Director/Board Member | 68 | 21-10-03 |
James Garner
CEO | Chief Executive Officer | - | 23-05-07 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-23 | 0.074 | -2.63% | 885,246 |
24-04-22 | 0.076 | +4.11% | 117,881 |
24-04-19 | 0.073 | -3.95% | 711,375 |
24-04-18 | 0.076 | 0.00% | 322,036 |
24-04-17 | 0.076 | -1.30% | 328,452 |
End-of-day quote Australian S.E., April 22, 2024
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+25.42% | 43.23M | |
-0.49% | 105B | |
+3.31% | 97.5B | |
+3.20% | 22.19B | |
-16.16% | 21.33B | |
-7.47% | 18.68B | |
-41.41% | 16.6B | |
-22.87% | 14.52B | |
+6.32% | 14.09B | |
+21.46% | 10.99B |
- Stock Market
- Equities
- PER Stock